Imperial College of Science, Technology and Medicine
The Chancellor, Masters and Scholars of the University of Oxford
Terveyden Ja Hyvinvoinnin Laitos
Rijksinstituut voor Volksgezondheid en Milieu
Stichting Nederlands Instituut voor Onderzoek van de Gezondheidzorg
Varsinais-Suomen Sairaanhoitopiirin Kuntayhtymä
TEAM IT Research, S.L.
Statens Serum Institut
Servizo Galego de Saúde
Fondazione PENTA ONLUS
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Sanofi Pasteur, S.A.
GlaxoSmithKline Biologicals, S.A.
Janssen Pharmaceuticals, N.V
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.